Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Atyr PHARMA in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings per share of ($0.78) for the year. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.91) per share.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02.
Several other brokerages have also commented on ATYR. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Wednesday, June 4th. Finally, Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Atyr PHARMA currently has an average rating of "Buy" and an average target price of $18.60.
Check Out Our Latest Research Report on Atyr PHARMA
Atyr PHARMA Stock Performance
ATYR traded up $0.04 during trading on Wednesday, reaching $5.43. The company's stock had a trading volume of 1,374,436 shares, compared to its average volume of 1,040,126. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $5.98. The company's fifty day moving average price is $3.70 and its 200-day moving average price is $3.58. The company has a market capitalization of $483.29 million, a price-to-earnings ratio of -5.78 and a beta of 0.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.
Institutional Investors Weigh In On Atyr PHARMA
A number of institutional investors have recently modified their holdings of the stock. Group One Trading LLC bought a new position in Atyr PHARMA in the 4th quarter worth $26,000. Victory Capital Management Inc. acquired a new position in Atyr PHARMA in the fourth quarter valued at about $37,000. Y Intercept Hong Kong Ltd acquired a new position in Atyr PHARMA in the first quarter valued at about $38,000. Raymond James Financial Inc. acquired a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $39,000. Finally, XTX Topco Ltd acquired a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $40,000. Institutional investors and hedge funds own 61.72% of the company's stock.
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Articles
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
